Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice

Neuropharmacology

Volumn 65, Issue , 2013, Pages 29-38

  Ago, Yukio ^a   Yano, Koji ^a   Araki, Ryota ^a   Hiramatsu, Naoki ^a   Kita, Yuki ^a   Kawasaki, Toshiyuki ^b   Onoe, Hirotaka ^b   Chaki, Shigeyuki ^c   Nakazato, Atsuro ^c   Hashimoto, Hitoshi ^a,d   Baba, Akemichi ^a,e   Takuma, Kazuhiro ^a   Matsuda, Toshio ^a,d  

^a OSAKA UNIVERSITY   (Japan)

^b RIKEN   (Japan)

^c TAISHO PHARMACEUTICAL CO LTD   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Chronic corticosterone; Depression; Dopamine; mGlu2 3 receptor antagonists; Prefrontal cortex

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; CORTICOSTERONE; DESIPRAMINE; DOPAMINE; FLUOXETINE; GLUTAMIC ACID; METABOTROPIC GLUTAMATE 2 RECEPTOR ANTAGONIST; METABOTROPIC GLUTAMATE 3 RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; POTASSIUM CHLORIDE; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DOSE COMPARISON; FORCED SWIMMING TEST; GLUTAMATE RELEASE; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SEROTONIN RELEASE; TREATMENT RESISTANT DEPRESSION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CORTICOSTERONE; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; PREFRONTAL CORTEX; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84870889349     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.09.008     Document Type: Article

References (67)

1. Y. Ago, R. Araki, K. Yano, N. Hiramatsu, T. Kawasaki, S. Chaki, A. Nakazato, H. Onoe, H. Hashimoto, A. Baba, K. Takuma, and T. Matsuda Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission Psychopharmacology (Berl.) 217 2011 443 452
2. Y. Ago, S. Arikawa, M. Yata, K. Yano, M. Abe, K. Takuma, and T. Matsuda Role of prefrontal dopaminergic neurotransmission in glucocorticoid receptor-mediated modulation of methamphetamine-induced hyperactivity Synapse 63 2009 7 14
3. Y. Ago, S. Arikawa, M. Yata, K. Yano, M. Abe, K. Takuma, and T. Matsuda Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression Neuropharmacology 55 2008 1355 1363
4. Y. Ago, T. Tanaka, Y. Kita, H. Tokumoto, K. Takuma, and T. Matsuda Lithium attenuates methamphetamine-induced hyperlocomotion and behavioral sensitization via modulation of prefrontal monoamine release Neuropharmacology 62 2012 1634 1639
5. 1 receptor activation Psychopharmacology (Berl.) 217 2011 377 386
6. R. Anwyl Metabotropic glutamate receptors: electrophysiological properties and role in plasticity Brain Res. Brain Res. Rev. 29 1999 83 120
7. 2A receptors Int. J. Neuropsychopharmacol. 13 2010 1299 1314
8. 2C receptor blockade restores the antidepressant-like effect of citalopram in non-responder mice Int. J. Neuropsychopharmacol. 12 2009 793 803
9. J. Camarero, V. Sanchez, E. O'Shea, A.R. Green, and M.I. Colado Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum J. Neurochem. 81 2002 961 972
10. J. Cartmell, K.W. Perry, C.R. Salhoff, J.A. Monn, and D.D. Schoepp Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade Neuropharmacology 40 2001 847 855
11. J. Cartmell, and D.D. Schoepp Regulation of neurotransmitter release by metabotropic glutamate receptors J. Neurochem. 75 2000 889 907
12. Chaki, S.; Ago, Y.; Palucha-Paniewiera, A.; Matrisciano, F.; Pilc, A. mGlu2/3 and mGlu5 receptors: potential target for novel antidepressants. Neuropharmacology, in press.
13. S. Chaki, R. Yoshikawa, S. Hirota, T. Shimazaki, M. Maeda, N. Kawashima, T. Yoshimizu, A. Yasuhara, K. Sakagami, S. Okuyama, S. Nakanishi, and A. Nakazato MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity Neuropharmacology 46 2004 457 467
14. J.F. Cryan, R.J. Valentino, and I. Lucki Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test Neurosci. Biobehav. Rev. 29 2005 547 569
15. G. Cuadra, A. Zurita, G. Gioino, and V. Molina Influence of different antidepressant drugs on the effect of chronic variable stress on restraint-induced dopamine release in frontal cortex Neuropsychopharmacology 25 2001 384 394
16. D.J. David, B.A. Samuels, Q. Rainer, J.W. Wang, D. Marsteller, I. Mendez, M. Drew, D.A. Craig, B.P. Guiard, J.P. Guilloux, R.P. Artymyshyn, A.M. Gardier, C. Gerald, I.A. Antonijevic, E.D. Leonardo, and R. Hen Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression Neuron 62 2009 479 493
17. T.G. Dinan Glucocorticoids and the genesis of depressive illness. A psychobiological model Br. J. Psychiatry 164 1994 365 371
18. C.H. Duman, L. Schlesinger, M. Kodama, D.S. Russell, and R.S. Duman A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment Biol. Psychiatry 61 2007 661 670
19. J.M. Dwyer, A.E. Lepack, and R.S. Duman mTOR activation is required for the antidepressant effects of mGluR2/3 blockade Int. J. Neuropsychopharmacol. 15 2012 429 434
20. K.B.J. Franklin, and G. Paxinos The Mouse Brain in Stereotaxic Coordinates 1997 Academic Press, Inc. San Diego
21. T.D. Gould, K.C. O'Donnell, E.R. Dow, J. Du, G. Chen, and H.K. Manji Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test Neuropharmacology 54 2008 577 587
22. S.L. Gourley, D.D. Kiraly, J.L. Howell, P. Olausson, and J.R. Taylor Acute hippocampal brain-derived neurotrophic factor restores motivational and forced swim performance after corticosterone Biol. Psychiatry 64 2008 884 890
23. S.L. Gourley, and J.R. Taylor Recapitulation and reversal of a persistent depression-like syndrome in rodents Curr. Protoc. Neurosci. 2009 49 (Chapter 9, Unit 9.32), 1-11
24. S.L. Gourley, F.J. Wu, D.D. Kiraly, J.E. Ploski, A.T. Kedves, R.S. Duman, and J.R. Taylor Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression Biol. Psychiatry 63 2008 353 359
25. A. Gregus, A.J. Wintink, A.C. Davis, and L.E. Kalynchuk Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats Behav. Brain Res. 156 2005 105 114
26. F. Holsboer, C.J. Lauer, W. Schreiber, and J.C. Krieg Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders Neuroendocrinology 62 1995 340 347
27. M. Iijima, A. Ito, S. Kurosu, and S. Chaki Pharmacological characterization of repeated corticosterone injection-induced depression model in rats Brain Res. 1359 2010 75 80
28. S.A. Johnson, N.M. Fournier, and L.E. Kalynchuk Effect of different doses of corticosterone on depression-like behavior and HPA axis responses to a novel stressor Behav. Brain Res. 168 2006 280 288
29. L.E. Kalynchuk, A. Gregus, D. Boudreau, and T.S. Perrot-Sinal Corticosterone increases depression-like behavior, with some effects on predator odor-induced defensive behavior, in male and female rats Behav. Neurosci. 118 2004 1365 1377
30. J. Karasawa, M. Kotani, D. Kambe, and S. Chaki AMPA receptor mediates mGlu 2/3 receptor antagonist-induced dopamine release in the rat nucleus accumbens shell Neurochem. Int. 57 2010 615 619
31. J. Karasawa, T. Shimazaki, N. Kawashima, and S. Chaki AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist Brain Res. 1042 2005 92 98
32. J. Karasawa, T. Yoshimizu, and S. Chaki A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell Neurosci. Lett. 393 2006 127 130
33. T. Kawasaki, Y. Ago, K. Yano, R. Araki, Y. Washida, H. Onoe, S. Chaki, A. Nakazato, H. Hashimoto, A. Baba, K. Takuma, and T. Matsuda Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice Neuropharmacology 60 2011 397 404
34. N. Kawashima, J. Karasawa, T. Shimazaki, S. Chaki, S. Okuyama, A. Yasuhara, and A. Nakazato Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors Neurosci. Lett. 378 2005 131 134
35. W.F. Kelly, S.A. Checkley, and D.A. Bender Cushing's syndrome, tryptophan and depression Br. J. Psychiatry 136 1980 125 132
36. P.J. Kenny, F. Gasparini, and A. Markou Group II metabotropic and α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats J. Pharmacol. Exp. Ther. 306 2003 1068 1076
37. Y. Kitamura, H. Araki, and Y. Gomita Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test Pharmacol. Biochem. Behav. 71 2002 63 69
38. H. Koike, M. Iijima, and S. Chaki Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists Neuropharmacology 61 2011 1419 1423
39. J.H. Krystal, S.J. Mathew, D.C. D'Souza, A. Garakani, H. Gunduz-Bruce, and D.S. Charney Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists CNS Drugs 24 2010 669 693
40. H. Kunugi, I. Ida, T. Owashi, M. Kimura, Y. Inoue, S. Nakagawa, T. Yabana, T. Urushibara, R. Kanai, M. Aihara, N. Yuuki, T. Otsubo, A. Oshima, K. Kudo, T. Inoue, Y. Kitaichi, O. Shirakawa, K. Isogawa, H. Nagayama, K. Kamijima, S. Nanko, S. Kanba, T. Higuchi, and M. Mikuni Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary- adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study Neuropsychopharmacology 31 2006 212 220
41. 1B autoreceptors limit the effects of selective serotonin re-uptake inhibitors in mouse hippocampus and frontal cortex J. Neurochem. 76 2001 865 871
42. R. Martinez-Turrillas, D. Frechilla, and J. Del Río Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus Neuropharmacology 43 2002 1230 1237
43. R.I. Melendez, M.L. Gregory, M.T. Bardo, and P.W. Kalivas Impoverished rearing environment alters metabotropic glutamate receptor expression and function in the prefrontal cortex Neuropsychopharmacology 29 2004 1980 1987
44. R.I. Melendez, J. Vuthiganon, and P.W. Kalivas Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors J. Pharmacol. Exp. Ther. 314 2005 139 147
45. B.E. Murphy, V. Dhar, A.M. Ghadirian, G. Chouinard, and R. Keller Response to steroid suppression in major depression on resistant to antidepressant therapy J. Clin. Psychopharmacol. 11 1991 121 126
46. B.E. Murphy, D. Filipini, and A.M. Ghadirian Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486 J. Psychiatry Neurosci. 18 1993 209 213
47. A. Palucha, and A. Pilc Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs Pharmacol. Ther. 115 2007 116 147
48. A. Pałucha-Poniewiera, J.M. Wierońska, P. Brański, K. Stachowicz, S. Chaki, and A. Pilc On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039 Psychopharmacology (Berl.) 212 2010 523 535
49. A. Pilc, S. Chaki, G. Nowak, and J.M. Witkin Mood disorders: regulation by metabotropic glutamate receptors Biochem. Pharmacol. 75 2008 997 1006
50. P.M. Plotsky, M.J. Owens, and C.B. Nemeroff Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis Psychiatr. Clin. North Am. 21 1998 293 307
51. Q. Rainer, L. Xia, J.P. Guilloux, C. Gabriel, E. Mocaër, R. Hen, E. Enhamre, A.M. Gardier, and D.J. David Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety Int. J. Neuropsychopharmacol. 15 2012 321 335
52. D.D. Schoepp Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system J. Pharmacol. Exp. Ther. 299 2001 12 20
53. T. Shimazaki, A. Kaku, and S. Chaki Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats Eur. J. Pharmacol. 575 2007 94 97
54. N. Sonino, M. Boscaro, G. Ambroso, G. Merola, and F. Mantero Prolonged treatment of Cushing's disease with metyrapone and aminoglutethimide IRCS J. Med. Sci. 14 1986 485 486
55. Y. Sugimoto, Y. Kajiwara, K. Hirano, S. Yamada, N. Tagawa, Y. Kobayashi, Y. Hotta, and J. Yamada Mouse strain differences in immobility and sensitivity to fluvoxamine and desipramine in the forced swimming test: analysis of serotonin and noradrenaline transporter binding Eur. J. Pharmacol. 592 2008 116 122
56. P. Svenningsson, E.T. Tzavara, J.M. Witkin, A.A. Fienberg, G.G. Nomikos, and P. Greengard Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac) Proc. Natl. Acad. Sci. U. S. A. 99 2002 3182 3187
57. C.J. Swanson, K.W. Perry, and D.D. Schoepp The mGlu2/3 receptor agonist, LY354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex J. Neurochem. 88 2004 194 202
58. 1A receptor agonist OPC-14523 Neuropharmacology 41 2001 976 988
59. 1)-receptor in the acute behavioral effects of antidepressants J. Pharmacol. Sci. 115 2011 279 292
60. J.M. Witkin, G.J. Marek, B.G. Johnson, and D.D. Schoepp Metabotropic glutamate receptors in the control of mood disorders CNS Neurol. Disord. Drug Targets 6 2007 87 100
61. P. Wlaź, R. Kasperek, A. Wlaź, M. Szumiło, A. Wróbel, G. Nowak, and E. Poleszak NMDA and AMPA receptors are involved in the antidepressant-like activity of tianeptine in the forced swim test in mice Pharmacol. Rep. 63 2011 1526 1532
62. O.M. Wolkowitz, V.I. Reus, F. Manfredi, J. Ingbar, L. Brizendine, and H. Weingartner Ketoconazole administration in hypercortisolemic depression Am. J. Psychiatry 150 1993 810 812
63. Z.X. Xi, D.A. Baker, H. Shen, D.S. Carson, and P.W. Kalivas Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens J. Pharmacol. Exp. Ther. 300 2002 162 171
64. T. Yoshimizu, and S. Chaki Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039 Biochem. Biophys. Res. Commun. 315 2004 493 496
65. T. Yoshimizu, T. Shimazaki, A. Ito, and S. Chaki An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats Psychopharmacology (Berl.) 186 2006 587 593
66. Y. Zhao, R. Ma, J. Shen, H. Su, D. Xing, and L. Du A mouse model of depression induced by repeated corticosterone injections Eur. J. Pharmacol. 581 2008 113 120
67. X. Zhuang, R.S. Oosting, S.R. Jones, R.R. Gainetdinov, G.W. Miller, M.G. Caron, and R. Hen Hyperactivity and impaired response habituation in hyperdopaminergic mice Proc. Natl. Acad. Sci. U. S. A. 98 2001 1982 1987